KCNMA1 and epilepsy: Zonisamide, as a commercially available antiepileptic drug, elicits an anticonvulsant effect by activating BK channels, and it reduces neuronal hyperexcitability by increasing BK channel currents.32 Therefore, this drug might be used to treat the epilepsy patients with NIPA2 loss‐of‐function mutation.